Literature DB >> 25658654

Comparison of clinical and angiographic prognostic risk scores in elderly patients presenting with acute coronary syndrome and referred for percutaneous coronary intervention.

Giuseppe Vassalli1, Ilaria d'Angeli2, Frank Scherff2, Daniel Sürder2, Antonio Mantovani2, Elena Pasotti2, Catherine Klersy3, Angelo Auricchio2, Tiziano Moccetti2, Giovanni B Pedrazzini2.   

Abstract

BACKGROUND: Multiple risk prediction models have been validated in all-age patients presenting with acute coronary syndrome (ACS) and treated with percutaneous coronary intervention (PCI); however, they have not been validated specifically in the elderly.
METHODS: We calculated the GRACE (Global Registry of Acute Coronary Events) score, the logistic EuroSCORE, the AMIS (Acute Myocardial Infarction Swiss registry) score, and the SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery) score in a consecutive series of 114 patients ≥75 years presenting with ACS and treated with PCI within 24 hours of hospital admission. Patients were stratified according to score tertiles and analysed retrospectively by comparing the lower/mid tertiles as an aggregate group with the higher tertile group. The primary endpoint was 30-day mortality. Secondary endpoints were the composite of death and major adverse cardiovascular events (MACE) at 30 days, and 1-year MACE-free survival. Model discrimination ability was assessed using the area under receiver operating characteristic curve (AUC).
RESULTS: Thirty-day mortality was higher in the upper tertile compared with the aggregate lower/mid tertiles according to the logistic EuroSCORE (42% vs 5%; odds ratio [OR] = 14, 95% confidence interval [CI] = 4-48; p <0.001; AUC = 0.79), the GRACE score (40% vs 4%; OR = 17, 95% CI = 4-64; p <0.001; AUC = 0.80), the AMIS score (40% vs 4%; OR = 16, 95% CI = 4-63; p <0.001; AUC = 0.80), and the SYNTAX score (37% vs 5%; OR = 11, 95% CI = 3-37; p <0.001; AUC = 0.77).
CONCLUSIONS: In elderly patients presenting with ACS and referred to PCI within 24 hours of admission, the GRACE score, the EuroSCORE, the AMIS score, and the SYNTAX score predicted 30 day mortality. The predictive value of clinical scores was improved by using them in combination.

Entities:  

Mesh:

Year:  2015        PMID: 25658654     DOI: 10.4414/smw.2015.14049

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  5 in total

1.  Predictive value of SYNTAX score II for clinical outcomes in octogenarian undergoing percutaneous coronary intervention.

Authors:  Evan Kurniawan; Feng-Hua Ding; Qi Zhang; Zhen-Kun Yang; Jian Hu; Wei-Feng Shen; Rui-Yan Zhang
Journal:  J Geriatr Cardiol       Date:  2016-09       Impact factor: 3.327

Review 2.  Antithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary syndrome.

Authors:  Alexandru Nicolae Mischie; Catalina Liliana Andrei; Crina Sinescu; Gani Bajraktari; Eugen Ivan; Georgios Nikolaos Chatziathanasiou; Michele Schiariti
Journal:  J Geriatr Cardiol       Date:  2017-07       Impact factor: 3.327

3.  Age-dependent impact of the SYNTAX-score on longer-term mortality after percutaneous coronary intervention in an all-comer population.

Authors:  Madeleine Eickhoff; Stefanie Schüpke; Alexander Khandoga; Julia Fabian; Moritz Baquet; David Jochheim; David Grundmann; Manuela Thienel; Axel Bauer; Hans Theiss; Stefan Brunner; Jörg Hausleiter; Steffen Massberg; Julinda Mehilli
Journal:  J Geriatr Cardiol       Date:  2018-09-28       Impact factor: 3.327

4.  Improved short and long term survival associated with percutaneous coronary intervention in the elderly patients with acute coronary syndrome.

Authors:  Xiaojing Chen; Salim Bary Barywani; Runa Sigurjonsdottir; Michael Fu
Journal:  BMC Geriatr       Date:  2018-06-07       Impact factor: 3.921

Review 5.  Contemporary Revascularization Dilemmas in Older Adults.

Authors:  Sonali Kumar; Michael McDaniel; Habib Samady; Farshad Forouzandeh
Journal:  J Am Heart Assoc       Date:  2020-01-24       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.